>>> LIFELINE BIOTECHN INC. <<< - 500 Beiträge pro Seite

[ECOLAB]

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company`s Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company.


Background
According to the American Cancer Society, breast cancer is the second leading cause of death in American women of all ages. For women 25-55, it is the leading cause of death. The incidence of breast cancer has more than doubled over the past 30 years and its prevalence continues to grow. This year alone, 245,000 women in the United States will be newly diagnosed with breast cancer and ductal carcinoma in-situ. An additional 45,000 women will die from previously diagnosed and, in the vast majority of instances, treated breast cancer. The number of women at high risk of breast cancer is expected to nearly double over the next 20 years to approximately 15 million.

It is estimated that 100 million mammograms are preformed worldwide. Currently, a woman living in the United States has a one in eight chance of developing breast cancer in her lifetime. Sadly, if the cancer is detected in the late stages of development, her survival rate is less than 20%. According to the National Institutes of Health, the medical costs associated with the disease for late-stage treatments are estimated to be more than $230,000 per patient. As the scientific community learns more about breast cancer, the number of women at risk increases.


The MastaScopeTM is designed to:

Visualize and inspect suspicious intraductal breast tissues and abnormalities undetectable by other modalities.
Provide a platform for intraductal procedures with direct visualization of the intraductal breast tissues and abnormalities of interest.
Complement existing diagnosis and treatment options with direct visualization observations.
Provide a platform of technology for real-time decisions and immediate intervention.




Technology that improves patient care.

Sharp accurate imagery.
MastaScope provides physicians with crystal clear, accurate imagery of intraductal breast tissues and abnormalities. The miniaturized scope and advanced fiber optic bundle allow surgeons to magnify breast tissue and pinpoint lesions as small as 0.15mm in diameter. The scope`s size allows it to be gradually advanced into peripheral sites to ensure thorough examinations.

Maximum patient comfort.
The procedure is minimally invasive and relatively painless. It can be performed under local anesthesia, in an outpatient setting, for maximum patient compliance and comfort.

Compact and portable.
The exclusive functional design of the MastaScope enhances ease of use and maneuverability translating into efficiency and convenience for physicians, staff and patients.

Cost-effective care.
With proper handling and sterilization, the MastaScope is suitable for multiple uses, making it a cost effective addition to the physician`s armamentarium.




Letzte NEWS:

Lifeline Biotechnologies Successfully Completes Testing of MastaScope Diagnostic Product in China.

RENO, Nev.--(BUSINESS WIRE)--Oct. 28, 2005--Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN - News) today announced that the Company has successfully completed the testing of MastaScope(TM) at three different hospitals in China. The MastaScope(TM) product provides sharp, clear, and accurate imagery of the intraductal breast tissues and abnormalities.
ADVERTISEMENT

The MastaScope(TM) was tested on 17 patients by Chinese surgeons under the direction of Dr. Pedro Escobar. Dr. Escobar is a Fellow in Breast and Gynecologic Oncology at the Cleveland Clinic Foundation. The surgeons were able to insert the MastaScope(TM), which is a micro-endoscope, through the patient`s nipple so the surgeon can examine the interior of the milk duct during the examination. Lifeline Biotechnologies already has been issued the Import Registration Number by the Chinese SDA, which is the equivalent to the American FDA.

"The MastaScope(TM) was very well received by chief breast surgeons at the Zheijang Province People`s Hospital, as well as the China-Japan Friendship Hospital and Beijing Third University Hospital. All the scopes and duct excisions were successful," stated Dr. Pedro Escobar.

"The completion of the testing of the MastaScope(TM) will enable us to continue with our strategy in entering the Chinese and Asian markets," stated Jim D. Holmes, CEO of Lifeline Biotechnologies, Inc.
www.lbti.com.

Outstanding Shares : 42,125,665 as of 2005-07-18

[ECOLAB]

RENO, Nev.--(BUSINESS WIRE)--Aug. 11, 2005--Lifeline Biotechnologies, Inc. (OTC:LBTN) today announced that Professor Kefah Mokbel, consultant breast surgeon at St. George`s Hospital and Medical School and Professor at Brunel Institute of Cancer Genetics & Pharmacogenomics and his research team in the UK have commenced a new study, examining the role of mammary ductoscopy, using MastaScope, in conjunction with dynamic thermal analysis, using the First Warning System and proteomics in the early detection of breast cancer.

This study has been approved by the Ethics` Committee at St. George`s Hospital Medical School in London. Participants include patients with suspected breast cancer, patients with benign breast disease, healthy volunteers and women who are known to harbor breast cancer causing genes (BRCA-1 or BRCA-2). Professor Mokbel believes that these novel strategies for breast cancer detection will complement screening mammography, which is regarded as the gold standard screening tool. Furthermore, mammary ductoscopy, using the MastaScope, may complement the role of dynamic thermal analysis in cases where these tests are positive, but anatomical imaging is negative for malignancy. This potential application may help resolve the issue of false-positive results, associated with screening tools based on physiological and biological principles. Researchers hope that if the preliminary results of this study are successful that they can be presented in the fifth European Breast Cancer Conference in France early next year.

Lifeline Biotechnologies has been in the process developing the First Warning System for a number of years and already markets the MastaScope. "We look forward to the results of Professor Mokbel`s study, as this is a major step in the commercialization and introduction to the market of our First Warning System," said Jim Holmes, chairman of Lifeline.

[ECOLAB]

Hier ein Interview mit Jim Holmes, CEO...

http://www.macreport.net/ceo_int/ceoint_asp.asp?symbol=LBTI

[ECOLAB]

http://quotes.barchart.com/texadv.asp?sym=LBTN

[ECOLAB]

Time & Sales
Price Size Exch Time
0.025 25000 OTO 10:41:23
0.026 25000 OTO 10:41:23
0.025 45000 OTO 10:40:42
0.026 45000 OTO 10:40:42
0.026 5000 OTO 10:40:12
0.024 25000 OTO 10:39:28
0.024 59601 OTO 10:39:21
0.024 40399 OTO 10:38:14
0.024 9601 OTO 10:37:28
0.023 60000 OTO 10:37:19
0.023 87200 OTO 10:36:49
0.023 50000 OTO 10:36:46
0.024 50000 OTO 10:36:40
0.023 43000 OTO 10:36:22
0.023 97501 OTO 10:35:56
0.024 50000 OTO 10:35:53
0.023 50000 OTO 10:35:31
0.024 50000 OTO 10:35:24
0.024 50000 OTO 10:34:38
0.023 12000 OTO 10:34:33
0.024 12000 OTO 10:34:26
0.023 50000 OTO 10:34:20
0.024 12000 OTO 10:34:15
0.024 50000 OTO 10:34:08
0.024 50000 OTO 10:34:04
0.024 50000 OTO 10:33:37
0.023 50000 OTO 10:32:55
0.023 50000 OTO 10:32:05
0.024 50000 OTO 10:32:03
0.024 20000 OTO 10:31:15

[ECOLAB]

Der Kurs ist deutlich zurück gekommen

Auf derzeitigem Niveau könnte man durchaus anfangen, eine kleine Position aufzubauen


Lifeline Biotechnologies, Inc. Has Potential To Revolutionize A Major Segment of the Medical Diagnostic Industry

RENO, Nev.--(BUSINESS WIRE)--Nov. 8, 2005--Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN-News - News) announced today that Mr. Jim Holmes, CEO has been interviewed on www.wallstreetcorner.com. In his editorial Larry Oakley, Publisher stated "in my opinion Lifeline Biotechnologies, Inc. has the potential to revolutionize a major segment of the medical diagnostic industry."

On his Web Site, Larry Oakley clearly defines the functionality and market potential for the MastaScope(TM). He points out that it can assist in detecting breast cancer several years prior to mammography.

According to his editorial, clinical evidence from studies has shown that the procedure utilizing the MastaScope(TM), minimally invasive mammary ductoscopy, is capable of visualizing lesions, which may be early stages of cancer, at dramatically smaller sizes than is currently possible through mammography. Clinical investigators have found breast cancer and premalignant breast lesions as small as 0.15mm in diameter, a lesion that would have to grow for another five to six years before mammography detection would be possible.

"I am very excited about the market potential for the MastaScope(TM). Moreover I am very optimistic about the life saving potential which can be achieved through early detection." stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

[ECOLAB]

[ECOLAB]

http://biz.yahoo.com/bw/051117/20051117005321.html?.v=1

http://biz.yahoo.com/bw/051129/20051129005160.html?.v=1


Das wird der "RENNER" in 2006

Eco